Topical otic, ophthalmic, and nasal corticosteroid formulations
US-2024000801-A1 · Jan 4, 2024 · US
Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
US9283232B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9283232-B2 |
| Application number | US-201314402548-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 3, 2013 |
| Priority date | Jun 14, 2012 |
| Publication date | Mar 15, 2016 |
| Grant date | Mar 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon administration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.
First claim
Opening claim text (preview).
What is claimed is: 1. A dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate, tiotropium bromide, and a carrier, said powder having an average particle size in a range of 30 to 120 μm. 2. The dry powder for inhalation formulation of claim 1 , whose average particle size is in a range of 55 to 65 μm. 3. The dry powder for inhalation formulation of claim 1 , wherein the carrier is selected from the gr…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9283232B2 cover?
- Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The inventive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribution in accordance with th…
- Who is the assignee on this patent?
- Hanmi Pharm Ind Co Ltd, Hanmi Pharm Ind Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/56. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).